What happened with VCYT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Veracyte analyzes gene activity in patient samples to give doctors information that routine clinical assessments may leave unresolved. Decipher Prostate estimates the risk that prostate cancer will spread, helping inform treatment decisions. Afirma helps identify benign thyroid nodules when an initial needle biopsy gives an inconclusive result. These two tests generate most of the company’s revenue.
In the United States, Veracyte performs testing in its own laboratories and bills commercial insurers, government programs such as Medicare and Medicaid, and patients. A significant share of revenue comes from a small group of payers, including Medicare and UnitedHealthcare Group. Outside the United States, it also sells Prosigna breast-cancer test kits to hospitals and laboratories, which perform the tests locally and seek reimbursement themselves.
The business depends on doctors ordering tests and payers agreeing to cover them at adequate rates; performing a test does not guarantee payment. Clinical evidence and medical guidelines help support both adoption and coverage. Its U.S. laboratories must maintain federal CLIA certification and required state licenses and test approvals to continue testing and billing.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Veracyte’s results hinge chiefly on adoption and reimbursement of Decipher and Afirma; watch Sonic Healthcare’s ThyroSeq, an important Afirma rival absent from this list.
MDxHealth SA’s GPS mdx competes with Veracyte’s Decipher for physicians choosing treatment or active surveillance for men with prostate cancer. Adoption of GPS mdx among urologists is worth watching because Decipher Prostate is one of Veracyte’s two main revenue sources.
Myriad Genetics Inc competes with Veracyte on two fronts: Prolaris helps physicians make prostate-cancer treatment decisions against Decipher Prostate, while EndoPredict competes with Veracyte’s breast-cancer testing. Watch those tests rather than Myriad’s overall results, which also include women’s-health and mental-health testing.
Natera is Veracyte’s primary rival in tests that monitor small amounts of cancer remaining after treatment—minimal residual disease, or MRD—for muscle-invasive bladder cancer. Its personalized blood-based cancer-monitoring tests are the relevant business to watch, rather than its prenatal or transplant testing.
Castle Biosciences, Inc. offers a comparison for Veracyte’s adoption and clinical-evidence progress: both sell molecular tests that use algorithms to assess cancer risk and guide care, but address different cancers. Watch use of Castle’s tissue-based skin-cancer tests, not as direct Decipher competition but as a read on specialists adopting this kind of testing.
Guardant Health and Veracyte both need physicians to use their genomic cancer tests and insurers to pay for them, with potential competition as Veracyte expands into residual-cancer monitoring. Watch Guardant’s oncology testing revenue and coverage for tests such as Guardant Reveal, rather than its drug-company services or screening business.
Personalis, Inc. already sells tests for residual cancer and recurrence in the market Veracyte is entering with its MRD technology. Watch clinical evidence for Personalis’s physician-facing monitoring tests, especially its claimed ability to detect recurrence before imaging, rather than its pharmaceutical research services.
Biodesix, Inc.’s blood-based Nodify tests address the same suspicious-lung-nodule risk decisions as Veracyte’s Percepta Nasal Swab, creating potential competition despite different sample types. Watch Nodify adoption by healthcare providers; Biodesix’s development services for research customers are less relevant to this tie.
Veracyte’s plan to let local laboratories run some molecular tests, including Prosigna, depends on Illumina’s NextSeq 550Dx platform; Illumina sells sequencing instruments and supplies to laboratories and hospitals. Watch progress toward offering Prosigna on that system in Canada, Europe, the Middle East, Asia Pacific and Latin America.
Illumina Inc earningsILMN
Illumina's report can show laboratories' demand for sequencing platforms, giving Veracyte a market signal for its plan to offer Prosigna as a locally run test outside the US.
If Illumina breaks out NextSeq 550Dx sales or use, read that alongside demand for its instruments overall. Stronger demand for the relevant platform would make the market setting more supportive of Veracyte's plan to offer Prosigna on that system; weaker demand would offer less support, but would not establish whether Veracyte's own work is on track. The report is a market signal, not confirmation of Veracyte's progress.
Biodesix, Inc. earningsBDSX
Biodesix's report can show whether healthcare providers are using Nodify more, offering a read on the lung-nodule diagnostic competition facing Veracyte's Percepta Nasal Swab.
Focus on any reported adoption of Biodesix's Nodify tests, not its research services. Rising use would show that more providers are using a blood test in suspicious-lung-nodule decisions, strengthening the alternative facing Percepta Nasal Swab; weak use would point to less competitive pressure, not prove that Veracyte's test is gaining ground. Nodify adoption shows how strong the competition is for these clinical decisions.
Veracyte, Inc. earningsThis company
Veracyte's report will show whether growth in Decipher and Afirma testing is still driving its main source of revenue.
Read Decipher and Afirma test volumes alongside testing revenue. Rising volumes and revenue together would show that more tests are translating into sales; slowing volumes, or revenue lagging volume, would flag weaker demand or less revenue per test. The combination shows whether Veracyte's core testing business is still expanding.
Myriad Genetics Inc earningsMYGN
If Myriad Genetics Inc reports use of Prolaris and EndoPredict, its results can show whether those tests are competing for the physician orders and payer support Veracyte's tests need.
Look for any reported use or sales trends for Prolaris and EndoPredict; Myriad's overall results also include businesses unrelated to these tests. Greater use of the two competing tests would signal stronger competition for physician orders and payer support in prostate and breast cancer testing; weaker use would mean less evidence of that pressure, not a guaranteed gain for Veracyte. The conclusion rests on what those specific tests show about competition.
Natera, Inc. earningsNTRA
Natera's report can show whether its personalized cancer-monitoring tests are gaining use and payer support, a signal of competition for Veracyte's bladder-cancer MRD tests.
Focus on reported use and payer coverage for Natera's personalized cancer-monitoring tests, especially where they relate to muscle-invasive bladder cancer; prenatal and transplant testing do not answer this question. Stronger use or coverage would show Natera gaining ground with the physicians and payers Veracyte also needs; weaker traction would mean less evidence of competitive pressure, not proof that Veracyte's tests are gaining adoption. The conclusion is how much competition Natera's progress presents in this specific market.
